Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr. Jay B. Saoud as senior vice president, head of research and development. His responsibilities will focus on the clinical development of the Company's portfolio of CNS products, including a Phase 3 trial with MIN-101 for schizophrenia, three Phase 2b trials with MIN-202 for major depressive disorder (MDD) and insomnia disorder and a Phase 2b trial with MIN-117 for MDD, all planned to begin in the second half of 2017, as well as the completion of pre-clinical development and subsequent initiation of clinical development with MIN-301 for Parkinson's disease.
Dr. Saoud brings to Minerva more than 25 years of research and development experience in both industry and academia, where he played a critical role in the design, conduct and reporting of clinical trials across multiple therapeutic areas including CNS. He was previously president and chief executive officer of PPRS Research, Inc., a strategic research and development consulting partner for Minerva. Dr. Saoud formerly served as a compound development team leader and head of exploratory development at Transform Pharmaceuticals (a Johnson & Johnson company), U.S. head of statistical sciences for clinical pharmacology and pharmacokinetics at Sanofi-Aventis and head of biometrics at ICOS Corporation.
"Dr. Saoud's hands-on experience in clinical development and regulatory activities will be invaluable as Minerva advances multiple product candidates into later-stage and pivotal clinical trials beginning this year," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "His wide-ranging skill set includes protocol development, clinical trial design and conduct, global regulatory strategy, pre-clinical expertise, pharmacology, pharmacokinetics and statistical sciences. Minerva has benefited significantly from Dr. Saoud's contributions as a consultant during the past several years, and we are delighted that he will now be working directly for the Company in a leadership position."
Dr. Saoud has been involved in the development of more than 125 active molecules in the central nervous system, diabetes, erectile dysfunction, hemorrhagic fever, muscular dystrophy, and multiple sclerosis areas. He has a record of successful pre-market and registration submissions in global regulatory jurisdictions and approval of 11 New Drug Applications (NDAs), 10 of which have resulted in sales in excess of $1 billion.
Dr. Saoud has published extensively in the areas of anxiety, depression, male erectile dysfunction, muscular dystrophy, and sleep, including more than 300 articles and abstracts primarily in peer-reviewed journals. Prior to his industry experience, he conducted clinical research at Columbia Presbyterian Medical Center/New York State Psychiatric Institute and was chief of mental health services within the New York City Department of Health's Correctional Facilities. He received his undergraduate degree in pre-medicine and psychology from the American University of Beirut, his master of science in Human Development from the University of Oregon, and his doctoral training in Experimental Cognition at City College of the City University of New York.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with MIN-101, MIN-202, MIN-117 and MIN-301. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101, MIN-202, MIN-117 and MIN-301 will advance further in the clinical trials process; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 3, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Early Warning Report23.5.2018 20:05 | Pressemelding
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) announces that pursuant to a warrant exercise, it has acquired for a purchase price of C$803,571, direct ownership of 5,357,142 common shares (the "Shares") of Prospero Silver Corp. ("Prospero"), of 510 West Georgia Street, Suite 1800, Vancouver, BC V6B 0M3, at a price of C$0.15 per Share. Immediately following this transaction, Fortuna owned 10,714,284 common shares of Prospero, representing 22.74% of the issued and outstanding common shares of Prospero. Immediately prior to the transaction, Fortuna owned 5,357,142 common shares and 5,357,142 common share purchase warrants. The Shares were acquired by Fortuna for investment purposes, and depending on market and other conditions, it may from time to time in the future increase or decrease its ownership, control or direction over securities of Prospero through market transactions, private agreements, or otherwise. Fortuna has fil
GaN Systems to Showcase Innovative GaN Power Technologies and Customer Solutions at PCIM Europe 201823.5.2018 15:00 | Pressemelding
Record-setting GaN transistors and an array of new products, design tools, and reference designs that make it easier to develop ground-breaking power systems will be displayed OTTAWA, May 23, 2018 (GLOBE NEWSWIRE) -- GaN Systems, the global leader in GaN (gallium nitride) power semiconductors, today announced that it will be exhibiting the company's new products and design tools and presenting customer demonstrations at PCIM Europe 2018 (Power Conversion and Intelligent Motion), Booth 511 in Hall 9 (9-511) from June 5-6, 2018 in Nuremberg, Germany. At PCIM Europe, one of the leading exhibitions for power electronics and its applications, attendees to the GaN Systems booth will learn about new products, the numerous IC companies that have collaborated with GaN Systems, and a vast array of customer implementations spanning the consumer, data center, industrial, and automotive market segments. Also, GaN Systems' subject matter experts will be speaking at four sessions over the course of t
Addiko Bank Implements Digital Banking Solutions on Appian23.5.2018 13:30 | Pressemelding
Digital Lending and Trade Finance applications cut customer wait times in half RESTON, Va., BELGRADE, Serbia and LJUBLJANA, Slovenia, May 23, 2018 (GLOBE NEWSWIRE) -- Appian (Nasdaq:APPN) and Addiko Bank, an international financial group headquartered in Vienna, Austria, today announced that the bank has deployed two new digital banking applications on Appian's low code application platform. The applications cover Lending and Trade Finance processes across Addiko's Corporate and Small Medium Enterprise (SME) customers. The applications have reduced customer wait times by as much as 50% by cutting "time to yes" for simple loans down from one week to just three days. Addiko Bank is the only financial group primarily focused on markets in the South Eastern Europe region (SEE), servicing more than 1 million customers. With these Appian deployments, Addiko Bank is the first bank within the SEE region to provide such a digital banking platform to customers in Slovenia and Serbia. Addiko is a
GMO Internet Group Offers GMO miner, The World's First Mining Machine Equipped with Mining Chips Using a Cutting-Edge 7 nm Process Technology: information session on Wednesday, June 623.5.2018 13:03 | Pressemelding
TOKYO, May 23, 2018 (GLOBE NEWSWIRE) -- Tokyo, Japan - May 23, 2018 - GMO Internet Group (https://www.gmo.jp/en/ ) will launch GMO miner (product name: GMO miner B2), which is our own high-performance computer for mining (mining machine), on Wednesday, June 6, 2018. We will mass-produce the world's first mining machine equipped with a cutting-edge 7 nm* process based semiconductor chip (7 nm mining chip; "GMO 72b"), which will be shipped at the end of October 2018. As a result, an information session for potential customers considering the purchase of GMO miner will be held on Wednesday, June 6 in Shibuya, Tokyo, and we will explain the details of GMO miner, such as price and performance. *nm: nanometer. 1/1 billion meters. 1/1 million millimeters. Selling "GMO miner" Cryptocurrency mining requires high-performance mining machines enabling highly sophisticated and intensive computation. Accordingly, GMO Internet Group has been working on research and development of a cutting-edge 7 nm
SolarWinds Extends Network Management Software Leadership with Deeper Visibility and Smarter Scalability23.5.2018 12:30 | Pressemelding
Software now simplifies management of complex networks with Network Insight for Cisco Nexus and intelligent mapping, supporting environments four times larger than previous generation AUSTIN, Texas, May 23, 2018 (GLOBE NEWSWIRE) -- SolarWinds, the worldwide leader in network management software, today announced a wave of updates to its network management product portfolio, which can now support networks up to four times larger than the previous generation. This significant gain makes it easy to consolidate monitoring solutions to a single provider enterprise-wise, and gives IT professionals far greater flexibility to scale up and support larger data center networks as workloads increase, or scale out to address complex distributed networks. SolarWinds says the broad refresh of its network management portfolio strengthens its IDC®-validated network management leadership position.1 Updated versions of Network Performance Monitor (NPM), Network Configuration Manager (NCM), IP Address Mana
VITEC to Showcase High-Quality, Low-Bandwidth Tactical Video Solutions at Eurosatory 201823.5.2018 10:00 | Pressemelding
VITEC Boosts Its ISR and Homeland Security Video Streaming and Dissemination Solutions With the World's Smallest Quad-Channel Rugged HEVC Encoder and a New Military-Grade IPTV Portal PARIS, May 23, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced it will showcase its latest high-performance video streaming solutions for military and defense applications at Eurosatory 2018. Scheduled for June 11-15 at Paris Nord Villepinte, Eurosatory is the premier international defense and security exhibition. "VITEC is strongly committed to providing every capability for processing and distributing Intelligence, Surveillance, and Reconnaissance (ISR) and situational awareness video generated in the field," said Richard Bernard, product manager, VITEC. "As a result of that commitment, we've added MGW Diamond TOUGH to our encoder lineup. The multichannel encoder streams up to eight video channels with extremely low bandwidth and low
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom